These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 28340268)
1. Is differential expression of p16INK4a based on the classification of uterine smooth muscle tumors associated with a different prognosis? A meta-analysis. Cao HY; Yang S; Wang S; Deng LY; Lou JY Genet Mol Res; 2017 Mar; 16(1):. PubMed ID: 28340268 [TBL] [Abstract][Full Text] [Related]
2. Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma. Zhang Q; Ubago J; Li L; Guo H; Liu Y; Qiang W; Kim JJ; Kong B; Wei JJ Cancer; 2014 Oct; 120(20):3165-77. PubMed ID: 24986214 [TBL] [Abstract][Full Text] [Related]
3. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581 [TBL] [Abstract][Full Text] [Related]
4. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. O'Neill CJ; McBride HA; Connolly LE; McCluggage WG Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074 [TBL] [Abstract][Full Text] [Related]
5. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma. Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023 [TBL] [Abstract][Full Text] [Related]
6. [Progress in clinicopathologic study on uterine smooth muscle tumor of uncertain malignant potential]. Deng ZJ; Guo LN Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):573-6. PubMed ID: 22169655 [No Abstract] [Full Text] [Related]
7. Prognostic Value of Overexpressed p16INK4a in Vulvar Cancer: A Meta-Analysis. Cao H; Wang S; Zhang Z; Lou J PLoS One; 2016; 11(3):e0152459. PubMed ID: 27031618 [TBL] [Abstract][Full Text] [Related]
8. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors. Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171 [TBL] [Abstract][Full Text] [Related]
9. Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond. Croce S; Chibon F Genes Chromosomes Cancer; 2021 Mar; 60(3):129-137. PubMed ID: 33099852 [TBL] [Abstract][Full Text] [Related]
10. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study. Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146 [TBL] [Abstract][Full Text] [Related]
12. Fascin expression in uterine smooth muscle tumors. Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633 [TBL] [Abstract][Full Text] [Related]
13. Genomic and Epigenomic Profile of Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMPs) Revealed Similarities and Differences with Leiomyomas and Leiomyosarcomas. Conconi D; Redaelli S; Lissoni AA; Cilibrasi C; Perego P; Gautiero E; Sala E; Paderno M; Dalprà L; Landoni F; Lavitrano M; Roversi G; Bentivegna A Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557274 [TBL] [Abstract][Full Text] [Related]
14. Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors. Soltan MM; Albasry AM; Eldosouky MK; Abdelhamid HS Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):7-12. PubMed ID: 29729689 [TBL] [Abstract][Full Text] [Related]
15. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas. Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921 [TBL] [Abstract][Full Text] [Related]
16. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases. Ip PP; Cheung AN; Clement PB Am J Surg Pathol; 2009 Jul; 33(7):992-1005. PubMed ID: 19417585 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of p16 expression in uterine smooth muscle tumors. Hakverdi S; Güngören A; Yaldiz M; Hakverdi AU; Toprak S Eur J Gynaecol Oncol; 2011; 32(5):513-5. PubMed ID: 22053664 [TBL] [Abstract][Full Text] [Related]
19. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma. Ozler A; Evsen MS; Turgut A; Sak ME; Tunc SY; Agacayak E; Alabalik U; Basaranoglu S; Keles AN; Gul T J Exp Ther Oncol; 2014; 10(4):325-30. PubMed ID: 25509988 [TBL] [Abstract][Full Text] [Related]
20. EMMPRIN (CD147) Expression in Smooth Muscle Tumors of the Uterus. Kefeli M; Yildiz L; Gun S; Ozen FZ; Karagoz F Int J Gynecol Pathol; 2016 Jan; 35(1):1-7. PubMed ID: 26352545 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]